07:00 , Oct 6, 2014 |  BC Week In Review  |  Company News

Shionogi sales and marketing update

Shionogi's C&O Pharmaceutical Technology (Holdings) Ltd. subsidiary launched rabeprazole sodium for injection in China to treat peptic ulcers. The company said the proton-pump inhibitor (PPI) is the only injectable rabeprazole product approved in China. The...
08:00 , Feb 17, 2014 |  BC Week In Review  |  Clinical News

Pariet rabeprazole regulatory update

Eisai disclosed in its earnings for the third quarter of the fiscal year ending March 31, 2014, that it submitted in November a regulatory application in Japan to expand the label of Pariet rabeprazole to...
08:00 , Feb 10, 2014 |  BioCentury  |  Finance

Confident roll of the dice(r)

Underwriters for Dicerna Pharmaceuticals Inc. 's IPO took the rare step of waiving a lockup period for the RNAi play - a move that could give some existing shareholders a free hand to immediately realize...
08:00 , Nov 18, 2013 |  BC Week In Review  |  Company News

Eisai sales and marketing update

Eisai launched 5 and 10 mg Aciphex Sprinkle delayed-release rabeprazole capsules in the U.S. to treat gastroesophageal reflux disease (GERD) for up to 12 weeks in children ages one to 11 years. FDA approved the...
08:00 , Nov 4, 2013 |  BioCentury  |  Finance

Calithera metabolizes

Calithera Biosciences Inc. has reinvented itself as a cancer metabolism play since it last raised money. A strong belief in the company's management lured back at least one existing investor in last week's $35 million...
07:00 , Aug 12, 2013 |  BC Week In Review  |  Clinical News

Pariet rabeprazole: Phase III started

Eisai disclosed in its 1Q13 earnings for the period ending June 30 that it began a Japanese Phase III trial to evaluate Pariet rabeprazole in patients resistant to PPIs. Eisai co-promotes a 20 mg tablet...
07:00 , Aug 5, 2013 |  BioCentury  |  Finance

Deciphering Dicerna's future

Dicerna Pharmaceuticals Inc .'s $60 million series C round last week attracted a syndicate of crossover investors that could usher the second-generation RNAi play to a public listing by this time next year. New investor...
07:00 , Apr 8, 2013 |  BC Week In Review  |  Clinical News

Aciphex Sprinkle delayed-release rabeprazole regulatory update

FDA approved 5 and 10 mg Aciphex Sprinkle delayed-release rabeprazole capsules treat gastroesophageal reflux disease (GERD) for up to 12 weeks in children ages 1-11 years. A 20 mg tablet formulation of Aciphex is approved...
08:00 , Feb 4, 2013 |  BioCentury  |  Finance

Northern exposure

Canadian VCs are hoping to benefit from a government initiative that will provide money to support their funds and attract institutional co-investors by offering as yet undefined financial incentives. Peter van der Velden of Montreal's...
08:00 , Jan 7, 2013 |  BC Week In Review  |  Clinical News

AciPhex regulatory update

On Dec. 11, 2012, Eisai said FDA granted pediatric exclusivity for Aciphex rabeprazole, which extends patent protection for the drug by 6 months to Nov. 8, 2013. A 20 mg tablet formulation of Aciphex is...